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Abstract
Chloroquine is a 9-aminoquinolone with well-known anti-malarial effects. It has biochemical
properties that could be applied to inhibit viral replication. We report here that chloroquine is able
to inhibit influenza A virus replication, in vitro, and the IC50s of chloroquine against influenza A
viruses H1N1 and H3N2 are lower than the plasma concentrations reached during treatment of
acute malaria. The potential of chloroquine to be added to the limited range of anti-influenza drugs
should be explored further, particularly since antiviral drugs play a vital role in influenza pandemic
preparedness.
Findings
Antiviral drugs against influenza virus play an important
role in the treatment and prevention of human influenza
infection. The adamantanes have been used for decades
and resistance to this class of drugs has become prevalent
in some parts of the world [1]. The neuraminidase inhib-
itor, oseltamivir, is currently regarded as the first line of
defence against a pandemic until a suitable vaccine can be
produced in sufficient quantities. Emergence of resistance
to this drug in human influenza A viruses [2], as well as
the H5N1 subtype in Vietnam [3] is thus a cause for con-
cern. Resistance has not been reported for zanamivir,
another neuraminidase inhibitor [4]. Expanding the range
of antiviral drugs that effectively inhibit influenza A virus
replication is thus a matter of urgency.
A recent review has suggested that the anti-malarial drug,
chloroquine, may have antiviral activity [5]. As a lyso-
somotropic weak base, it impairs replication of some
viruses through reducing the efficiency of endosome-
mediated virus entry or through inhibiting the low-pH
dependent proteases in trans-Golgi vesicles [5]. Its antivi-
ral activities against the human immunodeficiency virus
(HIV) [6] and the SARS coronavirus have been demon-
strated [7,8]. Previously, chloroquine had been used to
study influenza virus replication in vitro [9]. However, the
0.1 mM concentration used was too high to indicate its
therapeutic usefulness [9]. We thus carried out an in vitro
antiviral assay to determine the 50% and 90% inhibitory
concentration (IC50 and IC90, respectively) of chloro-
quine against influenza A virus subtypes H1N1 and
H3N2.
The in vitro antiviral screening assay was modified from a
previously described method [10] and carried out in trip-
licates. Influenza A viruses H1N1 (ATCC: VR1520) and
H3N2 (ATCC: VR544) were used in this study. Briefly, 50
µl of serial 2-fold dilutions of the chloroquine were incu-
bated overnight with 100 µl of MDCK cells giving a final
cell count of 30,000 cells per well in a 96-well microtitre
plate (Nunc A/S Roskilde, Denmark), for the drug to
equilibrate with the cells. 50 µl of virus at a concentration
Published: 29 May 2006
Virology Journal 2006, 3:39 doi:10.1186/1743-422X-3-39
Received: 31 March 2006
Accepted: 29 May 2006
This article is available from: http://www.virologyj.com/content/3/1/39
© 2006 Ooi et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Virology Journal 2006, 3:39 http://www.virologyj.com/content/3/1/39
Page 2 of 3
(page number not for citation purposes)
of 100 50% tissue culture infectivity dose (TCID50) was
added to each well and the plate incubated at 37°C in 5%
CO2 for 2 days. Viral replication was assessed by 2 meth-
ods: real-time RT-PCR using a previously described proto-
col [11] was carried out on nucleic acid extracted from the
supernatant of the culture, using the Roche Lightcycler
system (Roche Diagnostics, Mannheim, Germany); FITC-
labeled anti-nucleoprotein monoclonal antibody
(Chemicon International, Temecula, CA) was used to
stain the remaining cell monolayer and viewed under an
ultraviolet light microscope. Controls consisting of virus
and cell only, cell only, virus only and serial 2-fold dilu-
tion of amantadine in place of chloroquine were included
in each plate. Cytotoxicity of the drugs was also assessed
at all concentrations used in the antiviral assay.
The results are shown in Table 1 (see additional file 1).
Cellular toxicity was observed at a chloroquine concentra-
tion of 25 µM but not at higher dilutions. Complete inhi-
bition of influenza A virus H1N1 and H3N2 replication
was observed at 12.5 µM chloroquine. This was evident
microscopically with the absence of immunofluorescent
focus as well as a similar Ct value on real-time RT-PCR as
the virus only control. The number of fluorescent foci
increased with decreasing concentration of chloroquine
and this is similarly reflected in the decrease in Ct value of
the real time RT-PCR of their respective supernatant. The
IC50 and IC90 of chloroquine against H1N1 are 3.6 µM
and 9.9 µM, respectively, while those for H3N2 are 0.84
µM and 2.4 µM, respectively.
Only a handful of drugs are able to inhibit influenza A
virus replication and the increasing prevalence of resist-
ance to these drugs demands newer classes of anti-influ-
enza drugs. Although new compounds are still being
developed and their anti-influenza activity assessed, these
may take years to fulfill the regulatory requirements
before clinical use can be initiated. An alternative to this
mode of drug discovery may be to find new uses for old
drugs, where the availability of extensive experience with
their clinical use may shorten the duration needed for the
various phases of clinical trials. Chloroquine serves as
such an example. Our results suggest that chloroquine has
a clinically useful inhibitory activity against influenza A
virus replication.
The IC50 and IC90 for both the H1N1 and H3N2 viruses
are lower than the plasma concentration of chloroquine
that can be attained with dosages used in the prophylaxis
and treatment of acute malaria [12]. This suggests that the
dosages needed to inhibit human influenza A virus repli-
cation should be well tolerated by patients.
An added effect of chloroquine is its immunomodulatory
activity [5]. This may have an added benefit for the treat-
ment of influenza A (H5N1) infection since the pathology
of avian influenza infection in humans appears to be
mediated by pro-inflammatory cytokines [13].
Although we have shown that chloroquine is able to
inhibit two reference subtypes of influenza A viruses, test-
ing the susceptibility of a wide range of clinical isolates of
influenza A viruses to chloroquine, as well as in vivo stud-
ies, would be needed to determine the role, if any, of chlo-
roquine in the prophylaxis and treatment against
influenza infection. It would also be interesting to deter-
mine the activity of chloroquine against the highly patho-
genic H5N1 subtype as this would add to the very limited
antiviral stockpile against a possible pandemic.
In conclusion, chloroquine demonstrates an inhibitory
effect against the replication of human influenza A virus
H1N1 and H3N2, in vitro and further studies to explore
its therapeutic and prophylactic potential against influ-
enza epidemics and pandemics should be encouraged.
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